Metabolic changes associated with papillary thyroid carcinoma: A nuclear magnetic resonance-based metabolomics study

  • Authors:
    • Yanyun Li
    • Minjian Chen
    • Cuiping Liu
    • Yankai Xia
    • Bo Xu
    • Yanhui Hu
    • Ting Chen
    • Meiping Shen
    • Wei Tang
  • View Affiliations

  • Published online on: February 16, 2018     https://doi.org/10.3892/ijmm.2018.3494
  • Pages: 3006-3014
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Papillary thyroid carcinoma (PTC) is the most common thyroid cancer. Nuclear magnetic resonance (NMR)‑based metabolomic technique is the gold standard in metabolite structural elucidation, and can provide different coverage of information compared with other metabolomic techniques. Here, we firstly conducted NMR based metabolomics study regarding detailed metabolic changes especially metabolic pathway changes related to PTC pathogenesis. 1H NMR-based metabolomic technique was adopted in conju­nction with multivariate analysis to analyze matched tumor and normal thyroid tissues obtained from 16 patients. The results were further annotated with Kyoto Encyclopedia of Genes and Genomes (KEGG), and Human Metabolome Database, and then were analyzed using modules of pathway analysis and enrichment analysis of MetaboAnalyst 3.0. Based on the analytical techniques, we established the models of principal component analysis (PCA), partial least squares-discriminant analysis (PLS-DA), and orthogonal partial least-squares discriminant analysis (OPLS‑DA) which could discriminate PTC from normal thyroid tissue, and found 15 robust differentiated metabolites from two OPLS-DA models. We identified 8 KEGG pathways and 3 pathways of small molecular pathway database which were significantly related to PTC by using pathway analysis and enrichment analysis, respectively, through which we identified metabolisms related to PTC including branched chain amino acid metabolism (leucine and valine), other amino acid metabolism (glycine and taurine), glycolysis (lactate), tricarboxylic acid cycle (citrate), choline metabolism (choline, ethanolamine and glycerolphosphocholine) and lipid metabolism (very-low‑density lipoprotein and low-density lipoprotein). In conclusion, the PTC was characterized with increased glycolysis and inhibited tricarboxylic acid cycle, increased oncogenic amino acids as well as abnormal choline and lipid metabolism. The findings in this study provide new insights into detailed metabolic changes of PTC, and hold great potential in the treatment of PTC.

Introduction

Thyroid cancer is the most common cancer in the endocrine system. The incidence of thyroid cancer is increasing every year in the United States, and the increase is not only because of the better diagnosis technique for thyroid cancers. There are estimated to be ~123,000 people in the world who are diagnosed thyroid cancer cases annually, accounting for approximately over 91.5% of the cancers of head and neck (1). Notably, papillary thyroid carcinoma (PTC) is the most common type of all thyroid cancers, which accounts for ~80% of the thyroid cancers.

Metabolomics is an emerging omics technology, and it can systematically identify and quantify metabolites in a biological sample. The technology development of nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) allows the simultaneous analysis of various chemicals in the biological sample, and therefore NMR and MS are the favorable platforms for metabolomic analysis (2). Metabolomics has been widely used in studies regarding diseases (3), and it identifies metabolic signatures which are related to the pathogenesis of the diseases (35). There are metabolomic studies on PTC based on gas chromatography-mass spectrometry (GC-MS) (6,7). Compared with GC-MS, NMR is generally accepted as the gold standard in metabolite structural elucidation, which is highly selective, non-destructive for chemical detection. Additionally, the metabolite coverage is different between NMR and GC-MS (8). Therefore, different metabolomic information can be provided by NMR and GC-MS. There are limited published metabolomic studies regarding PTC using NMR (911), but these studies focused on the diagnosis of PTC, and therefore the detailed metabolic changes especially metabolic pathway changes related to PTC pathogenesis are still largely unknown. Given these facts, it is necessary to adopt NMR based metabolomics technology to study the detailed metabolic changes and disturbed metabolic pathways in PTC.

We used 1H NMR-based metabolomic technique to study the metabolic changes in PTC. We established reliable statistical models which could well discriminate and predict the tumor and normal thyroid tissue. Based on these models and further bioinformatics analysis, we identified detailed metabolic changes and disturbed metabolic pathways in PTC.

Patients and methods

Basic patient information and sample collection

A total of 16 patients (4 males, 12 females; age range, 19–59 years; tumor size, 1–4.2 cm) had undergone surgical thyroidectomy at the First Affiliated Hospital of Nanjing Medical University. Previous metabolomic studies using cancer tissues have proved that similar sample number and characteristics of the population can provide useful information on metabolic changes of cancer (4,911). Matched normal thyroid tissues and tumor tissues were obtained from the same PTC patients. The diagnosis was confirmed by histopathologic evaluation based on the established criteria of WHO (12), which was conducted independently by two pathologists. The analyzed tumor tissues which contained over 90% cancer cells were obtained by using microdissection, and normal tissues were not connected by follicular adenomas (FAs) or PTC. The patients were not received radiation therapy or neo-adjuvant chemotherapy before operation. All tissues were immediately frozen in liquid nitrogen, and then stored at −80°C until NMR analysis. The study was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University, and each participant signed an informed consent.

1H NMR spectroscopy based metabolomic analysis

Metabolomic analysis was conducted according to metabolomic procedure for NMR spectroscopy of tissues (13). The metabolomic analysis was performed with Bruker Avance III 600 NMR spectrometer. Tissue samples were placed in a 4 mm rotor, and 5 µl aliquot of deuterium oxide was added into the rotor. The resonance frequency of 1H was 400 MHz, and the experimental temperature was 298 K. A Carr-Purcell-Meiboom-Gill (CPMG) filter was included in the pulse sequence to reduce broad resonances related to background or macromolecules. After the fourier transformation, the spectra was manually phased and baseline corrected, and then referenced to lactic acid CH3 resonance at δ1.33.

Multivariate pattern recognition

In order to discriminate the samples according to tissue types and identify potential biomarkers in relation to PTC, principal component analysis (PCA), partial least squares-discriminant analysis (PLS-DA), and the orthogonal partial least-squares discriminant analysis (OPLS-DA) were applied using the normalized NMR data. We identified changed metabolites in PTC by using OPLS-DA statistical model. SIMCA-P + software (v11.0; Umetrics AB, Umea, Sweden) was used for data analysis. The correlation coefficient of |r| >0.482 and the variable importance in projection (VIP) value >1.00 were used as cut-off value of the statistical significance based on the discrimination significance at the level of P=0.05.

Biological significance interpretation and informatics analysis

To identify detailed metabolic changes and disturbed metabolic pathways, the differentiated metabolites were first annotated with 'Kyoto Encyclopedia of Genes and Genomes' (KEGG, http://www.genome.jp/kegg/or http://www.kegg.jp/) which is a knowledge library for systematic analysis of metabolite functions and networks and 'Human Metabolome Database' (HMDB, http://www.hmdb.ca/) which is a complete and comprehensive database on metabolomics with metabolite biological interpretation (14,15). Further, we conducted informatics analysis by MetaboAnalyst 3.0 (http://www.metaboanalyst.ca/MetaboAnalyst/) which is built by R software (v3.2.2) (16). MetaboAnalyst combines the results from powerful pathway enrichment analysis with the pathway topology analysis to discover the relevant pathways. Two modules of MetaboAnalyst including pathway analysis and enrichment analysis were used. The module of pathway analysis was based on the KEGG database; the enrichment analysis was conducted based on Small Molecule Pathway Database (SMPDB, http://smpdb.ca/) (17).

Results

Metabolomic profiling

Fig. 1 shows the workflow of this metabolomic study. The metabolomic profiles obtained from PTC and normal thyroid tissue are shown in Fig. 2. The metabolic profiling covered branched chain amino acids (isoleucine, leucine and valine), other proteinogenic amino acids (alanine, phenylalanine, tyrosine, glycine, aspartate, glutamate and lysine), and product of amino acid (creatine) as well as amino acid derivatives (sarcosine and taurine). Metabolites involved in the nucleotide metabolism (hypoxanthine, uracil, uridine and allantoin), glycolysis (lactate), tricarboxylic acid cycle (citrate and succinate), choline metabolism (choline, ethanolamine, glycerolphosphocholine and N,N-dimethylglycine) and lipid metabolism [very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL) and lipids] were also profiled.PCA. PCA is the most commonly used algorithm in metabolomics studies (18). We adopted PCA in the study to process the NMR data based on a mean center-scaling model, which is an unsupervised projection method used to visualize the dataset and display the intrinsic similarity and difference in the dataset. As shown in Fig. 3 (19), the PTC tissues were clearly discriminated from normal tissues using PCA model, indicating dramatic metabolic changes in PTC. The PCA model descriptors (R2X, Q2) were 0.79/0.75, indicating the model was reliable.

PLS-DA

PLS-DA was further conducted to evaluate the data variance between PTC and normal tissue. As shown in Fig. 4A (20), PLS-DA score plot showed a statistically significant discrimination between the two groups based on the mean center-scaling model (R2X= 0.79, R2Y= 0.71, Q2= 0.66). Similar significant discrimination between the two groups was also observed based on the unit variance scaling model (R2X=0.26, R2Y= 0.82, Q2=0.71) (Fig. 4B) (20). To test the validity of the PLS-DA models, the robustness of the models was assessed using a 200-permutations validation model, which showed that the originally observed separation was not due to a random effect, as the predictive discrimination values of the random models were all lower than that of the original model.

OPLS-DA

Additional OPLS-DA was conducted to establish the mean center-scaling model and the unit variance scaling model. The mean center-scaling model descriptors (R2X, Q2) were 0.79/0.66 (Fig. 5A), and the unit variance scaling mode descriptors (R2X, Q2) were 0.26/0.77 (Fig. 5B), indicating these models were reliable.

Differential metabolites in PTC

Based on the unit variance scaling OPLS-DA model, there were 26 differential metabolites identified. The differential metabolites in PTC are presented in Table I and Fig. 5B. To find the robustly changed metabolites, we verified the changed metabolites in the mean center-scaling model, which identified 16 differential metabolites (Table II and Fig. 5A), among which 15 consistently changed metabolites were found (Table III).

Table I

OPLS-DA coefficients derived from the NMR data of metabolites in thyroid obtained from PTC and normal tissue in the unit variance scaling mode.

Table I

OPLS-DA coefficients derived from the NMR data of metabolites in thyroid obtained from PTC and normal tissue in the unit variance scaling mode.

Metabolitesra
Alanine: 1.48(db)0.738
Choline: 3.20(s)0.758
Citrate: 2.57(d), 2.69(d)−0.792
Creatine: 3.04(s), 3.93(s)0.594
Ethanolamine: 3.14(t), 3.85(t)0.858
Glutamate: 2.15(m), 2.35(m), 3.78(t)0.831
Glycine: 3.56(s)0.566
Glycerophosphocholine: 3.23(s), 3.35(s)0.754
Isoleucine: 0.94(d), 1.01(d)0.597
Inosine: 6.10(d), 8.23(s), 8.34(s)0.897
L1, LDL, CH3–(CH2)n–: 0.86(br)0.732
L2, VLDL, CH3–(CH2)n–: 0.90(br)−0.762
L3, VLDL, CH3–(CH2)n–: 1.29(br)−0.628
L4, VLDL, –CH2–CH2–C=O: 1.59(br)−0.822
L5, Lipid, –CH2–C=O: 2.26(br)−0.738
Lactate: 1.33(d), 4.11(q)0.893
Leucine: 0.96(t)0.767
Lysine: 1.72(m), 1.91(m), 3.01(m), 1.76(t)0.750
N-acetyl glycoprotein signals: 2.03(s)0.520
Phenylalanine: 7.33(d), 7.37(t), 7.43(dd)0.759
Taurine: 3.28(t), 3.43(t)0.861
Tyrosine: 6.90(d), 7.20(d)0.532
Unknown-1: 1.07(m)0.854
Unknown-2: 2.06(m)−0.679
Uridine diphosphate glucose: 5.61(dd), 5.98(m), 7.96(d)0.569
Valine: 0.99(d), 1.04(d)0.889

a Correlation coefficients, positive and negative signs indicate positive and negative correlation in the concentrations, respectively. The correlation coefficient of |r| >0.482 was used as the cut-off value for the statistical significance based on the discrimination significance at the level of P=0.05 and df (degree of freedom) = 15.

b Multiplicity: s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; m, multiplet; br, broad resonance; OPLS-DA, orthogonal partial least-squares discriminant analysis; NMR, nuclear magnetic resonance; PTC, papillary thyroid carcinoma.

Table II

VIP value derived from the NMR data of metabolites in thyroid obtained from PTC and normal tissue in the mean center-scaling model.

Table II

VIP value derived from the NMR data of metabolites in thyroid obtained from PTC and normal tissue in the mean center-scaling model.

MetabolitesVIPa
Lactate: 1.33(db), 4.11(q)10.81
L3, VLDL, CH3–(CH2)n–: 1.29(d)9.81
Glycerophosphocholine: 3.23(s), 3.35(s)9.24
Unknown-1: 1.07(m)3.63
L1, LDL, CH3–(CH2)n–: 0.86(br)3.05
Valine: 0.99(d), 1.04(d)2.81
L2, VLDL, CH3–(CH2)n–: 0.90(br)2.62
Taurine: 3.28(t), 3.43(t)2.44
N-acetyl glycoprotein signals: 2.03(s)2.29
Myo-inositol: 3.56(dd), 3.63(dd), 4.06(t)2.19
Citrate: 2.57(d), 2.69(d)1.81
Leucine: 0.96(t)1.63
Ethanolamine: 3.14(t), 3.85(t)1.63
Choline: 3.20(s)1.26
Unknown-2: 2.06(m)1.13
Glycine: 3.56(s)1.04

a The VIP value >1.00 was used as the cut-off value for the statistical significance based on the discrimination significance at the level of P=0.05.

b Multiplicity: s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; m, multiplet; br, broad resonance; VIP, variable importance in projection; NMR, nuclear magnetic resonance; PTC, papillary thyroid carcinoma.

Table III

The consistently changed metabolites in thyroid obtained from PTC and normal tissue in the OPLS-DA models.

Table III

The consistently changed metabolites in thyroid obtained from PTC and normal tissue in the OPLS-DA models.

MetabolitesKEGGHMDBraVIPbPathway
CholineC00114HMDB00970.7581.26Choline metabolism
EthanolamineC00189HMDB01490.8581.63Choline metabolism
GlycerophosphocholineC00670HMDB00860.7549.24Choline metabolism
LactateC00186HMDB01900.89310.81Glycolysis
CitrateC00158HMDB0094−0.7921.81Tricarboxylic acid cycle
LeucineC00123HMDB06870.7671.63Branched chain amino acid metabolism
ValineC00183HMDB08830.8892.81Branched chain amino acid metabolism
GlycineC00037HMDB01230.5661.04Other amino acid metabolism
TaurineC00245HMDB02510.8612.44Other amino acid metabolism
L1, LDLNANA0.7323.05Lipid metabolism
L2, VLDLNANA−0.7622.62Lipid metabolism
L3, VLDLNANA−0.6289.81Lipid metabolism
N-acetyl glycoprotein signalsNANA0.5202.29NA
Unknown-1: 1.07(m)NANA0.8543.63NA
Unknown-2: 2.06(m)NANA−0.6791.13NA

a Correlation coefficients derived from the unit variance scaling model, positive and negative signs indicate positive and negative correlation in the concentrations, respectively. The correlation coefficient of |r| >0.482 was used as the cut-off value for the statistical significance based on the discrimination significance at the level of P=0.05 and df=15.

b The VIP value derived from the mean center-scaling model >1.00 was used as the cut-off value for the statistical significance based on the discrimination significance at the level of P=0.05. PTC, papillary thyroid carcinoma; OPLS-DA, orthogonal partial least-squares discriminant analysis; NA, not available; df, degrees of freedom.

Metabolic pathway analysis and biological significance interpretation

The 15 metabolites related to PTC with robust results were then annotated with KEGG and HMDB (Table III). The results were submitted to MetaboAnalyst to show the statistical analysis results of informatics analysis. The result of pathway analysis is shown in Table IV and Fig. 6A, which found 8 pathways including glycerophospholipid metabolism, aminoacyl-tRNA biosynthesis, valine, leucine and isoleucine biosynthesis, propanoate metabolism, nitrogen metabolism, valine, leucine and isoleucine degradation, primary bile acid biosynthesis, and glycine, serine and threonine metabolism were significantly related to PTC. Furthermore, in order to expand the understanding of metabolic pathway related to PTC, the module of enrichment analysis of MetaboAnalyst was used, which found 3 additional pathways including protein biosynthesis, phospholipid biosynthesis and methionine metabolism significantly related to PTC (Table V and Fig. 6B). Finally, based on biological significance and the above informatics analysis, the metabolic network related to PTC was built (Fig. 7), which indicated the key metabolisms related to PTC including branched chain amino acid metabolism (leucine and valine), other amino acid metabolism (glycine and taurine), glycolysis (lactate), tricarboxylic acid cycle (citrate), choline metabolism (choline, ethanolamine and glycerolphosphocholine) and lipid metabolism (VLDL and LDL).

Table IV

Pathway analysis of metabolic changes in PTC.a

Table IV

Pathway analysis of metabolic changes in PTC.a

KEGG pathwayTotalExpectedHitsImpactP-value
Glycerophospholipid metabolism390.14630.0873.09E-04
Aminoacyl-tRNA biosynthesis750.28030.0002.13E-03
Valine, leucine and isoleucine biosynthesis270.10120.0274.16E-03
Propanoate metabolism350.13120.0006.94E-03
Nitrogen metabolism390.14620.0008.57E-03
Valine, leucine and isoleucine degradation400.15020.0229.01E-03
Primary bile acid biosynthesis470.17620.0161.23E-02
Glycine, serine and threonine metabolism480.17920.1881.28E-02
Cyanoamino acid metabolism160.06010.0005.84E-02
Citrate cycle (TCA cycle)200.07510.0637.25E-02
Taurine and hypotaurine metabolism200.07510.3317.25E-02
Ether lipid metabolism230.08610.0008.29E-02
Thiamine metabolism240.09010.0008.64E-02
Pantothenate and CoA biosynthesis270.10110.0009.67E-02
Glycolysis or gluconeogenesis310.11610.0001.10E-01
Pyruvate metabolism320.12010.1381.14E-01
Methane metabolism340.12710.0001.20E-01
Glutathione metabolism380.14210.0001.34E-01
Lysine degradation470.17610.0001.63E-01
Glyoxylate and dicarboxylate metabolism500.18710.0031.72E-01
Purine metabolism920.34410.0002.96E-01
Porphyrin and chlorophyll metabolism1040.38910.0003.28E-01

a The analysis was conducted by the module of pathway analysis of MetaboAnalyst 3.0. PTC, papillary thyroid carcinoma; KEGG, Kyoto Encyclopedia of Genes and Genomes.

Table V

Pathway enrichment of metabolic changes in PTC.a

Table V

Pathway enrichment of metabolic changes in PTC.a

Pathway from SMPDBTotalExpectedHitsP-value
Protein biosynthesis190.20721.64E-02
Phospholipid biosynthesis190.20721.64E-02
Methionine metabolism240.26222.58E-02
Valine, leucine and isoleucine degradation360.39325.50E-02
Taurine and hypotaurine metabolism70.07617.42E-02
Bile acid biosynthesis490.53529.52E-02
Glutathione metabolism100.10911.04E-01
Betaine metabolism100.10911.04E-01
Ammonia recycling180.19611.81E-01
Propanoate metabolism180.19611.81E-01
Pyruvate metabolism200.21811.99E-01
Porphyrin metabolism220.24012.17E-01
Citric acid cycle230.25112.26E-01
Glycine, serine and threonine metabolism260.28412.51E-01
Gluconeogenesis270.29512.60E-01

a The analysis was conducted by the module of enrichment analysis of MetaboAnalyst 3.0. PTC, papillary thyroid carcinoma; SMPDB, Small Molecule Pathway Database.

Discussion

Based on the rapid development of analytical techniques, metabolomics has been applied in many fields such as biochemical and clinical study (2124). In the study of human diseases, metabolomics takes advantage of novel biomarker exploration and pathophysiological interpretation at the molecular level (2124). However, until now, there are only NMR-based metabolomic studies focusing on the diagnosis of PTC (911), and therefore the detailed metabolic changes potentially related to PTC pathogenesis are still largely unknown. In this study, based on the results of PCA, PLS-DA, OPLS-DA models (Figs. 3Figure 45), we first identified key metabolites related to PTC (Table III). Then, after KEGG and HMDB annotation and following pathway and enrichment analysis, we found significant metabolic pathways related to PTC (Fig. 6), through which we found the metabolic network related to PTC, indicating the metabolic changes potentially related to PTC pathogenesis (Fig. 7).

Robust changes of metabolite levels in PTC included increased lactate, which participates in significantly changed KEGG pathway of propanoate metabolism directly related to glycolysis. The significant increase of lactate in other cancers such as colon cancer and prostate cancer has been reported in previous studies (25,26). This metabolic response in PTC indicated an increase of the glycolytic flux due to hypoxia and ischemia in the tumor tissues or the consequence of the so-called 'Warburg effect', producing more waste products such as lactate (27). Previous GC-MS based metabolomics study did not monitor lactate but found the increased expression of the gene LDHA encoding lactate dehydrogenase which catalyzes the synthesis of lactate in PTC (7), which was consistent with the present study. Citrate which was a significantly decreased metabolite in PTC tissue participates in the tricarboxylic acid cycle which is directly related to glycolysis. Previous study also revealed that the decreased tricarboxylic acid cycle was accompanied by increased glycolytic flux in gastric cardia cancer due to decreased pyruvic acid efflux into the tricarboxylic acid cycle (28). Normal tricarboxylic acid cycle may have an inhibitory effect on cancer progression (28). Collectively, these findings revealed increased glycolysis and inhibited tricarboxylic acid cycle in PTC, which may be biologically related to PTC pathogenesis.

Notably, the robust changes of amino acids in PTC include leucine and valine. Leucine and valine were also included in significantly changed KEGG pathway such as amino acyl-tRNA biosynthesis, and valine, leucine and isoleucine biosynthesis and degradation as well as SMPDB pathway including protein biosynthesis. Branched-chain amino acids include isoleucine, leucine and valine. Recent metabolomics studies have consistently revealed that branched-chain amino acids is positively related to obesity (29) and diabetes (23,29), which are both endocrine abnormalities and associated with the risk of PTC (30). In the unit variance scaling mode, isoleucine was also identified as the biomarker with increased level in PTC. Additionally, isoleucine and leucine have been identified as tumor promoters of bladder cancer (31). Glycine is involved in the body's production of DNA, phospholipids and collagen, as well as in release of energy. It participates in significantly changed KEGG pathways such as glycine, serine and threonine metabolism. It is reported that glycine plays an important role in rapid cancer cell proliferation (32). Amino acid derivative, the increase of taurine was found in PTC. Taurine was identified as a possible fingerprint biomarker in non-muscle invasive bladder cancer (33). It participates in significantly changed KEGG pathways of aminoacyl-tRNA biosynthesis, indicating the abnormal protein biosynthesis in PTC. As suggested by Tessem et al in colon cancer, the increase of taurine may reflect an imbalance in osmolyte function in cancer cells (25). Therefore, the increased levels of branched chain amino acids, glycine and taurine in PTC should attract attention as they may be the oncogenic biomarkers of PTC 29).

Significant KEGG pathway including glycerophospholipid metabolism and SMPDB pathways including phospholipid biosynthesis as well as methionine metabolism both are related to choline metabolism covering choline, ethanolamine and glycerophosphocholine. Glycerophosphorylcholine is a choline derivative and one of the major forms of choline storage. Indeed, the abnormal choline metabolism has been reported in breast cancer (34). As indicated in SMPDB, choline metabolism is related to the body methylation status which is associated with thyroid carcinoma pathogenesis (35). In this study, the metabolites in lipid metabolism including VLDL and LDL also changed in PTC. This finding is consistent with blood lipid profile alterations in another malignant disease, acute lymphoblastic leukemia (36).

It is urgent to seek new biomarkers for thyroid carcinoma. Metabolomic profiles from tissue have the potential to be used in conjunction with current diagnostics to help guide the clinical management of patients with PTC (911). Our study not only established robust multivariate analysis models that could discriminate PTC, but also identified robust metabolic signatures of PTC based on different statistical models. The robustly changed metabolites identified in this study may be used as potential biomarkers for PTC, among which consistent results were found on lactate and taurine in another metabolomics study regarding PTC (10).

In conclusion, in this study, we found that the metabolomic profiling could discriminate PTC in conjunction with multivariate analysis, and identified robust metabolic signatures of PTC. After informatics analysis, we found the PTC is characterized with increased glycolysis and inhibited tricarboxylic acid cycle, increased oncogenic amino acids as well as abnormal choline and lipid metabolism, which needs further research to deeply study the underlying mechanism and the usage of the study findings in the intervention of PTC. The findings in this study provide new insights into metabolic changes of PTC, and hold great potential in the treatment of PTC.

Glossary

Abbreviations

Abbreviations:

PTC

papillary thyroid carcinoma

NMR

nuclear magnetic resonance

KEGG

Kyoto Encyclopedia of Genes and Genomes

HMDB

human metabolome database

PCA

principal component analysis

PLS-DA

partial least squares discriminant analysis

OPLS-DA

orthogonal partial least-squares discriminant analysis

SMPDB

Small Molecule Pathway Database

VLDL

very-low-density lipoprotein

LDL

low-density lipoprotein

MS

mass spectrometry

GC-MS

gas chromatography-mass spectrometry

VIP

variable importance in the projection

FAs

follicular adenomas

CPMG

Carr-Purcell-Meiboom-Gill

Acknowledgments

Not applicable.

Notes

[1] Funding

The present study was supported by the National Natural Science Foundation (no. 81770773), the Natural Science Foundation of Jiangsu Province (no. BK20171499); the Jiangsu Province Key Medical Talents (co-construction) Program, the Talent Project of '333' Project in Jiangsu Province, the Jiangsu Province Official Hospital Scientific Research Initial Funding (no. RPF201501), the Jiangsu Province Official Hospital Talents Construction Fund Research Project (no. IR2015101), the National Natural Science Foundation (no. 81402713), the Young Scholars of Jiangsu Province (no. BK20140909), the Innovation Fund Project of the State Key Laboratory of Reproductive Medicine (general) (no. SKLRM-GA201802). The funding bodies had no role in the design of the study or collection, analysis, and interpretation of data or in writing the manuscript.

[2] Availability of data and material

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

[3] Authors' contributions

YL performed the metabolomic analysis and drafted the manuscript. MC analyzed and interpreted the metabolomic data, and made substantial contributions to manuscript revision. CL participated in sample collection and sample preparation for metabolomic analysis. YX provided analytical tools, and contributed to study design and metabolic network establishment. BX was a major contributor in sample preparation, and participated in the instrumental analysis. YH performed metabolic pathway analysis, and prepared figures. TC participated in multivariate pattern recognition analysis and table preparation. MS collected the sample, and was a major contributor in study design. WT made substantial contributions to conception and design, and was involved in acquisition of data and manuscript revision. All authors read and approved the final manuscript.

[4] Ethics approval and consent to participate

The study was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University, and each participant signed an informed consent.

[5] Consent for publication

The participants provided written informed consent for the publication of any associated data and accompanying images.

[6] Competing interests

The authors declare that they have no competing interests.

References

1 

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI

2 

Cheng LL, Burns MA, Taylor JL, He W, Halpern EF, McDougal WS and Wu CL: Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res. 65:3030–3034. 2005. View Article : Google Scholar : PubMed/NCBI

3 

Brindle JT, Antti H, Holmes E, Tranter G, Nicholson JK, Bethell HW, Clarke S, Schofield PM, McKilligin E, Mosedale DE, et al: Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med. 8:1439–1444. 2002. View Article : Google Scholar : PubMed/NCBI

4 

Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, et al: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 457:910–914. 2009. View Article : Google Scholar : PubMed/NCBI

5 

El-Bacha T, Struchiner CJ, Cordeiro MT, Almeida FC, Marques ET Jr and Da Poian AT: 1H nuclear magnetic resonance metabolomics of plasma unveils liver dysfunction in dengue patients. J Virol. 90:7429–7443. 2016. View Article : Google Scholar : PubMed/NCBI

6 

Shang X, Zhong X and Tian X: Metabolomics of papillary thyroid carcinoma tissues: potential biomarkers for diagnosis and promising targets for therapy. Tumour Biol. 37:11163–11175. 2016. View Article : Google Scholar : PubMed/NCBI

7 

Chen M, Shen M, Li Y, Liu C, Zhou K, Hu W, Xu B, Xia Y and Tang W: GC-MS-based metabolomic analysis of human papillary thyroid carcinoma tissue. Int J Mol Med. 36:1607–1614. 2015. View Article : Google Scholar : PubMed/NCBI

8 

Pan Z and Raftery D: Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal Bioanal Chem. 387:525–527. 2007. View Article : Google Scholar

9 

Jordan KW, Adkins CB, Cheng LL and Faquin WC: Application of magnetic-resonance-spectroscopy-based metabolomics to the fine-needle aspiration diagnosis of papillary thyroid carcinoma. Acta Cytol. 55:584–589. 2011. View Article : Google Scholar

10 

Miccoli P, Torregrossa L, Shintu L, Magalhaes A, Chandran J, Tintaru A, Ugolini C, Minuto MN, Miccoli M, Basolo F, et al: Metabolomics approach to thyroid nodules: a high-resolution magic-angle spinning nuclear magnetic resonance-based study. Surgery. 152:1118–1124. 2012. View Article : Google Scholar : PubMed/NCBI

11 

Deja S, Dawiskiba T, Balcerzak W, Orczyk-Pawiłowicz M, Głód M, Pawełka D and Młynarz P: Follicular adenomas exhibit a unique metabolic profile. 1H NMR studies of thyroid lesions. PLoS One. 8:e846372013. View Article : Google Scholar

12 

DeLellis RA, Lloyd RV, Heitz PU and Eng C: Organization Classification of Tumours Pathology and Genetics of Tumours of Endocrine Organs. 8. 3rd edition. IARC Press; Lyon: 2004

13 

Jordan KW, Nordenstam J, Lauwers GY, Rothenberger DA, Alavi K, Garwood M and Cheng LL: Metabolomic characterization of human rectal adenocarcinoma with intact tissue magnetic resonance spectroscopy. Dis Colon Rectum. 52:520–525. 2009. View Article : Google Scholar : PubMed/NCBI

14 

Du J, Yuan Z, Ma Z, Song J, Xie X and Chen Y: KEGG-PATH: Kyoto Encyclopedia of Genes and Genomes-based pathway analysis using a path analysis model. Mol Biosyst. 10:2441–2447. 2014. View Article : Google Scholar : PubMed/NCBI

15 

Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, Djoumbou Y, Mandal R, Aziat F, Dong E, et al: HMDB 3.0 - the Human Metabolome Database in 2013. Nucleic Acids Res. 41:D801–D807. 2013. View Article : Google Scholar

16 

Xia J, Sinelnikov IV, Han B and Wishart DS: Metabo-Analyst 3.0 - making metabolomics more meaningful. Nucleic Acids Res. 43:W251–W257. 2015. View Article : Google Scholar : PubMed/NCBI

17 

Frolkis A, Knox C, Lim E, Jewison T, Law V, Hau DD, Liu P, Gautam B, Ly S, Guo AC, et al: SMPDB: The Small Molecule Pathway Database. Nucleic Acids Res. 38(Suppl 1): D480–D487. 2010. View Article : Google Scholar :

18 

Anthony ML, Rose VS, Nicholson JK and Lindon JC: Classification of toxin-induced changes in 1H NMR spectra of urine using an artificial neural network. J Pharm Biomed Anal. 13:205–211. 1995. View Article : Google Scholar : PubMed/NCBI

19 

Lamour SD, Straschil U, Saric J and Delves MJ: Changes in metabolic phenotypes of Plasmodium falciparum in vitro cultures during gametocyte development. Malar J. 13:468–478. 2014. View Article : Google Scholar : PubMed/NCBI

20 

Bahety P, Tan YM, Hong Y, Zhang L, Chan EC and Ee PL: Metabotyping of docosahexaenoic acid - treated Alzheimer's disease cell model. PLoS One. 9:e901232014. View Article : Google Scholar : PubMed/NCBI

21 

Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, et al: Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 472:57–63. 2011. View Article : Google Scholar : PubMed/NCBI

22 

Zhang Y, Dai Y, Wen J, Zhang W, Grenz A, Sun H, Tao L, Lu G, Alexander DC, Milburn MV, et al: Detrimental effects of adenosine signaling in sickle cell disease. Nat Med. 17:79–86. 2011. View Article : Google Scholar

23 

Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, et al: Metabolite profiles and the risk of developing diabetes. Nat Med. 17:448–453. 2011. View Article : Google Scholar : PubMed/NCBI

24 

Chen M, Zhou K, Chen X, Qiao S, Hu Y, Xu B, Xu B, Han X, Tang R, Mao Z, et al: Metabolomic analysis reveals metabolic changes caused by bisphenol A in rats. Toxicol Sci. 138:256–267. 2014. View Article : Google Scholar : PubMed/NCBI

25 

Tessem MB, Selnaes KM, Sjursen W, Tranø G, Giskeødegård GF, Bathen TF, Gribbestad IS and Hofsli E: Discrimination of patients with microsatellite instability colon cancer using 1H HR MAS MR spectroscopy and chemometric analysis. J Proteome Res. 9:3664–3670. 2010. View Article : Google Scholar : PubMed/NCBI

26 

Tessem MB, Swanson MG, Keshari KR, Albers MJ, Joun D, Tabatabai ZL, Simko JP, Shinohara K, Nelson SJ, Vigneron DB, et al: Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn Reson Med. 60:510–516. 2008. View Article : Google Scholar : PubMed/NCBI

27 

Koppenol WH, Bounds PL and Dang CV: Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 11:325–337. 2011. View Article : Google Scholar : PubMed/NCBI

28 

Cai Z, Zhao JS, Li JJ, Peng DN, Wang XY, Chen TL, Qiu YP, Chen PP, Li WJ, Xu LY, et al: A combined proteomics and metabolomics profiling of gastric cardia cancer reveals characteristic dysregulations in glucose metabolism. Mol Cell Proteomics. 9:2617–2628. 2010. View Article : Google Scholar : PubMed/NCBI

29 

Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA, et al: A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 9:311–326. 2009. View Article : Google Scholar : PubMed/NCBI

30 

Cheng SP, Chi CW, Tzen CY, Yang TL, Lee JJ, Liu TP and Liu CL: Clinicopathologic significance of leptin and leptin receptor expressions in papillary thyroid carcinoma. Surgery. 147:847–853. 2010. View Article : Google Scholar : PubMed/NCBI

31 

Nishio Y, Kakizoe T, Ohtani M, Sato S, Sugimura T and Fukushima S: L-isoleucine and L-leucine: tumor promoters of bladder cancer in rats. Science. 231:843–845. 1986. View Article : Google Scholar : PubMed/NCBI

32 

Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, Souza AL, Kafri R, Kirschner MW, Clish CB and Mootha VK: Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science. 336:1040–1044. 2012. View Article : Google Scholar : PubMed/NCBI

33 

Srivastava S, Roy R, Singh S, Kumar P, Dalela D, Sankhwar SN, Goel A and Sonkar AA: Taurine - a possible fingerprint biomarker in non-muscle invasive bladder cancer: a pilot study by 1H NMR spectroscopy. Cancer Biomark. 6:11–20. 2010. View Article : Google Scholar

34 

Katz-Brull R, Seger D, Rivenson-Segal D, Rushkin E and Degani H: Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res. 62:1966–1970. 2002.PubMed/NCBI

35 

Venkataraman GM, Yatin M, Marcinek R and Ain KB: Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I symporter gene methylation status. J Clin Endocrinol Metab. 84:2449–2457. 1999.PubMed/NCBI

36 

Halton JM, Nazir DJ, McQueen MJ and Barr RD: Blood lipid profiles in children with acute lymphoblastic leukemia. Cancer. 83:379–384. 1998. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

May-2018
Volume 41 Issue 5

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li Y, Chen M, Liu C, Xia Y, Xu B, Hu Y, Chen T, Shen M and Tang W: Metabolic changes associated with papillary thyroid carcinoma: A nuclear magnetic resonance-based metabolomics study. Int J Mol Med 41: 3006-3014, 2018
APA
Li, Y., Chen, M., Liu, C., Xia, Y., Xu, B., Hu, Y. ... Tang, W. (2018). Metabolic changes associated with papillary thyroid carcinoma: A nuclear magnetic resonance-based metabolomics study. International Journal of Molecular Medicine, 41, 3006-3014. https://doi.org/10.3892/ijmm.2018.3494
MLA
Li, Y., Chen, M., Liu, C., Xia, Y., Xu, B., Hu, Y., Chen, T., Shen, M., Tang, W."Metabolic changes associated with papillary thyroid carcinoma: A nuclear magnetic resonance-based metabolomics study". International Journal of Molecular Medicine 41.5 (2018): 3006-3014.
Chicago
Li, Y., Chen, M., Liu, C., Xia, Y., Xu, B., Hu, Y., Chen, T., Shen, M., Tang, W."Metabolic changes associated with papillary thyroid carcinoma: A nuclear magnetic resonance-based metabolomics study". International Journal of Molecular Medicine 41, no. 5 (2018): 3006-3014. https://doi.org/10.3892/ijmm.2018.3494